Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.24.3
Stockholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity [Line Items]  
Schedule of Warrant and Stock Option Grants with Time-Based Vesting The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the three months ended March 31, 2024 were:
    Warrant Grants     Stock Option Grants     Restricted
Stock
Units		  
    Number of
shares
subject to
warrants		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
options		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
restricted
stock units		  
Balance at December 31, 2023     11,394     $ 58.72       3,333     $ 39.60       165,663  
Granted    
-
      
-
      
-
      
-
       21,405  
Exercised    
-
      
-
      
-
      
-
       (23,072 )
Cancelled/Expired     (2,293 )     53.64      
-
      
-
      
-
  
Balance at March 31, 2024     9,101     $ 60.00       3,333     $ 39.60       163,996  
Exercisable at March 31, 2024     9,101     $ 60.00       3,333     $ 39.60       163,996  
The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the three months ended March 31, 2023 were:
    Warrant Grants     Stock Option Grants     Restricted
Stock
Units		  
    Number of
shares
subject to
warrants		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
options		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
restricted
stock units		  
Balance at December 31, 2022     104,515     $ 20.25       7,889     $ 48.75       160,650  
Granted     -       -      
-
      
-
       22,667  
Exercised    
-
      
-
      
-
      
-
       (755 )
Cancelled/Expired     (1,446 )     124.95      
-
      
-
      
-
  
Balance at March 31, 2023     103,069     $ 18.60       7,889     $ 48.75       182,562  
Exercisable at March 31, 2023     103,069     $ 18.60       7,889     $ 48.75       160,809  
Schedule of Stock-Based Compensation Expense Stock-based compensation expense for three months ended March 31, 2024 is 2023 was as follows:
    For the three months ended  
    March 31,  
    2024     2023  
Stock-based compensation expense   $ -     $ 147,873  
Warrant [Member]  
Stockholders' Equity [Line Items]  
Schedule of Company’s Outstanding Warrants and Options The Company’s outstanding warrants and options at March 31, 2024 are as follows:
Warrants Outstanding     Warrants Exercisable  
Exercise Price
Range		     Number
Outstanding		     Weighted Average
Remaining
Contractual Life
(in years)		     Weighted
Average
Exercise 
Price		     Number
Exercisable		     Weighted
Average
Exercise Price		     Intrinsic Value  
$ 60.00       9,101       1.76     $ 60.00       9,101     $ 60.00      
-
  
Options Outstanding     Options Exercisable  
Exercise Price
Range		     Number
Outstanding		     Weighted Average
Remaining
Contractual Life
(in years)		     Weighted
Average
Exercise
Price		     Number
Exercisable		     Weighted
Average
Exercise Price		     Intrinsic Value  
$ 39.60       3,333       .66     $ 39.60       3,333     $ 39.60      
-